Cerecor Inc. (CERC) to Release Quarterly Earnings on Monday
Cerecor (NASDAQ:CERC) last announced its earnings results on Monday, August 14th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.15. Cerecor had a negative return on equity of 1,325.84% and a negative net margin of 1,106.99%. The business had revenue of $0.16 million during the quarter. On average, analysts expect Cerecor to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of Cerecor Inc. (CERC) opened at $1.12 on Friday. Cerecor Inc. has a fifty-two week low of $0.34 and a fifty-two week high of $5.60.
TRADEMARK VIOLATION WARNING: “Cerecor Inc. (CERC) to Release Quarterly Earnings on Monday” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/cerecor-inc-cerc-to-release-quarterly-earnings-on-monday/1679472.html.
In related news, major shareholder Armistice Capital Master Fund bought 954,228 shares of Cerecor stock in a transaction dated Wednesday, August 16th. The stock was acquired at an average cost of $0.61 per share, with a total value of $582,079.08. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last ninety days, insiders have bought 1,638,693 shares of company stock valued at $1,053,475. 10.70% of the stock is currently owned by company insiders.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.